Definitive Healthcare (NASDAQ:DH - Get Free Report)'s stock had its "hold" rating restated by equities researchers at Needham & Company LLC in a research note issued to investors on Wednesday, Benzinga reports.
A number of other brokerages have also issued reports on DH. Stifel Nicolaus decreased their target price on shares of Definitive Healthcare from $12.00 to $11.00 and set a "buy" rating on the stock in a research report on Wednesday, January 17th. Barclays raised their price target on Definitive Healthcare from $10.00 to $11.00 and gave the stock an "equal weight" rating in a research report on Friday, March 1st. Canaccord Genuity Group increased their price target on shares of Definitive Healthcare from $9.00 to $10.00 and gave the stock a "hold" rating in a research report on Thursday, February 29th. Finally, Morgan Stanley downgraded Definitive Healthcare from an "overweight" rating to an "equal weight" rating and reduced their target price for the company from $11.50 to $9.00 in a report on Wednesday. Eight research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $10.81.
Check Out Our Latest Research Report on Definitive Healthcare
Definitive Healthcare Stock Down 26.2 %
DH stock traded down $1.90 during mid-day trading on Wednesday, reaching $5.35. The company had a trading volume of 5,266,618 shares, compared to its average volume of 613,781. Definitive Healthcare has a 52 week low of $4.38 and a 52 week high of $12.45. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.31 and a quick ratio of 2.31. The stock has a 50 day simple moving average of $7.78 and a two-hundred day simple moving average of $8.31. The company has a market capitalization of $630.18 million, a price-to-earnings ratio of -2.84, a PEG ratio of 6.12 and a beta of 1.41.
Definitive Healthcare (NASDAQ:DH - Get Free Report) last issued its quarterly earnings data on Wednesday, February 28th. The company reported ($0.01) EPS for the quarter, missing analysts' consensus estimates of $0.01 by ($0.02). Definitive Healthcare had a negative net margin of 80.40% and a positive return on equity of 0.43%. The firm had revenue of $65.93 million during the quarter, compared to analyst estimates of $66.01 million. As a group, equities analysts predict that Definitive Healthcare will post 0.11 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Definitive Healthcare
A number of hedge funds have recently added to or reduced their stakes in the stock. Susquehanna Fundamental Investments LLC bought a new position in Definitive Healthcare in the 1st quarter worth approximately $120,000. Swiss National Bank increased its holdings in Definitive Healthcare by 2.9% in the 1st quarter. Swiss National Bank now owns 103,300 shares of the company's stock valued at $834,000 after acquiring an additional 2,900 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its stake in Definitive Healthcare by 40.5% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 49,393 shares of the company's stock worth $399,000 after purchasing an additional 14,229 shares in the last quarter. Norden Group LLC bought a new position in shares of Definitive Healthcare during the 1st quarter valued at about $83,000. Finally, Principal Financial Group Inc. purchased a new position in shares of Definitive Healthcare during the first quarter valued at about $290,000. 98.67% of the stock is currently owned by hedge funds and other institutional investors.
Definitive Healthcare Company Profile
(
Get Free Report)
Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.
Read More
Before you consider Definitive Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Definitive Healthcare wasn't on the list.
While Definitive Healthcare currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
